Abstract:
Aim: To evaluate efficacy of biopreparations by lymphocyte sensitivity in vitro in children
with chronic hepatitis B (CHB). Methods: 47 children with CHB were studied at the age 3-14 years with intestinal dysbacteriosis (ID): II (21.3%); III (38.3%); IV (40.4%). Test in vitro used to body sensitivity to Lacto-G, Narimax-plus and Bifilax-immuno (UZ IAP 04570, 2022). Biocorrection of ID was performed on basic therapy with use of highly sensitive for body biopreparation. Group of comparison of 20 patients with CHB receiving Bifidum- and Lactobacterin.